pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
354
stories
16h
Bristol Myers defends pipeline, reinforces later-stage BD interest
endpoints
18h
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
20h
LENZ cuts 75% of staff as third quarter earnings disappoint
biospace
1d
BMS walks away from $80M neurodegeneration bet after phase 1
fiercebiotech
1d
STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings
stat
1d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
2d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
2d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
2d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
2d
5 new drug launches that defied industry expectations
biospace
2d
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
stat
2d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
2d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
3d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
3d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
3d
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
stat
3d
STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmacies
stat
3d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
3d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
3d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
3d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
3d
STAT+: Five biotech updates to read after ESMO this weekend
stat
3d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
3d
BMS joins 3-year partnership to boost participation in cancer trials
fiercebiotech
3d
Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing
fiercebiotech
4d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
4d
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
endpoints
4d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
5d
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
endpoints
5d
STAT+: The ESMO presentation everyone’s been waiting for
stat
← prev
page 1 of 12
next →
